المؤلفون: Ribi, K, Luo, WX, Colleoni, M, Karlsson, P, Chirgwin, J, Aebi, S, Jerusalem, G, Neven, P, Di Lauro, V, Gomez, HL, Ruhstaller, T, Abdi, E, Biganzoli, L, Mueller, B, Barbeaux, A, Graas, MP, Rabaglio, M, Francis, PA, Foukakis, T, Pagani, O, Graff, C, Vorobiof, D, Maibach, R, Di Leo, A, Gelber, RD, Goldhirsch, A, Coates, AS, Regan, MM, Bernhard, J

المصدر: British journal of cancer. 120(10):959-967

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:140920600Test

المؤلفون: Ribi, K, Luo, WX, Colleoni, M, Karlsson, P, Chirgwin, J, Aebi, S, Jerusalem, G, Neven, P, Di Lauro, V, Gomez, HL, Ruhstaller, T, Abdi, E, Biganzoli, L, Muller, B, Barbeaux, A, Graas, MP, Rabaglio, M, Francis, PA, Foukakis, T, Pagani, O, Graiff, C, Vorobiof, D, Maibach, R, Di Leo, A, Gelber, RD, Goldhirsch, A, Coates, AS, Regan, MM, Bernhard, J

المصدر: British journal of cancer. 122(7):1119-1119

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:142827594Test

المؤلفون: Buono G., Arpino G., Del Mastro L., Fabi A., Generali D., Puglisi F., Zambelli A., Cinieri S., Nuzzo F., Di Lauro V., Vigneri P., Bianchini G., Montemurro F., Gennari A., De Laurentiis M.

المساهمون: Buono, G., Arpino, G., Del Mastro, L., Fabi, A., Generali, D., Puglisi, F., Zambelli, A., Cinieri, S., Nuzzo, F., Di Lauro, V., Vigneri, P., Bianchini, G., Montemurro, F., Gennari, A., De Laurentiis, M.

مصطلحات موضوعية: aromatase inhibitor, breast cancer, clinical and genomic risk, Delphi study, extended endocrine treatment, ovarian function suppression, premenopausal patient, tamoxifen

الوصف: The use of an aromatase inhibitor (AI) in combination with ovarian function suppression (OFS) has become the mainstay of adjuvant endocrine therapy in high-risk premenopausal patients with hormone receptor-positive breast cancer. Although five years of such therapy effectively reduces recurrence rates, a substantial risk of late recurrence remains in this setting. Multiple trials have shown that extending AI treatment beyond five years could offer further protection. However, as these studies comprised only postmenopausal patients, no direct evidence currently exists to inform about the potential benefits and/or side effects of extended AI + OFS therapies in premenopausal women. Given these grey areas, we conducted a Delphi survey to report on the opinion of experts in breast cancer treatment and summarize a consensus on the discussed topics. A total of 44 items were identified, all centred around two main themes: 1) defining reliable prognostic factors to pinpoint premenopausal patients eligible for endocrine therapy extension; 2) designing how such therapy should optimally be administered in terms of treatment combinations and duration based on patients’ menopausal status. Each item was separately discussed and anonymously voted by 12 experts representing oncological institutes spread across Italy. The consensus threshold was reached in 36 out of 44 items (82%). Herein, we discuss the levels of agreement/disagreement achieved by each item in relation to the current body of literature. In the absence of randomized trials to guide the tailoring of extended AI treatment in premenopausal women, conclusions from our study provide a framework to assist routine clinical practice.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000882170500001; volume:12; firstpage:1032166; journal:FRONTIERS IN ONCOLOGY; https://hdl.handle.net/11390/1237747Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85141734504

الإتاحة: https://doi.org/10.3389/fonc.2022.1032166Test
https://hdl.handle.net/11390/1237747Test

المؤلفون: Di Lauro V., Barchiesi G., Martorana F., Zucchini G., Muratore M., Fontanella C., Arpino G., Del Mastro L., Giuliano M., Puglisi F., De Laurentiis M.

المساهمون: Di Lauro, V., Barchiesi, G., Martorana, F., Zucchini, G., Muratore, M., Fontanella, C., Arpino, G., Del Mastro, L., Giuliano, M., Puglisi, F., De Laurentiis, M.

مصطلحات موضوعية: abemaciclib, cyclin-dependent 4/6 inhibitor, health-related quality of life, palbociclib, ribociclib

الوصف: Background: Evaluation of health-related quality of life (HR-QoL) among cancer patients has gained an increasing importance and is now a key determinant of anticancer treatments’ value. HR-QoL has been assessed in trials testing cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in breast cancer (BC), using various questionnaires at different timepoints. HR-QoL reports from BC patients treated with CDK4/6i in the real-world setting are also available. Methods: We systematically reviewed the literature, searching for full-length articles, and selected conference abstracts reporting data on HR-QoL in BC patients at any stage and of any molecular subtype treated with abemaciclib, palbociclib or ribociclib. Results: A total of 533 full-length articles and 143 abstracts were retrieved. After screening for eligibility, 38 records were included (31 clinical trials; 7 real-world reports). Assessment methods were heterogeneous across studies in terms of questionnaires, evaluation timepoints and endpoints. Overall, adding CDK4/6i to endocrine therapy did not worsen patients’ HR-QoL, with a positive trend towards pain improvement. Gastrointestinal scores (diarrhea, nausea and appetite loss) statistically favored the control arm among metastatic BC patients receiving abemaciclib, whereas they were superimposable in the early setting. The combination of palbociclib and endocrine therapy showed similar HR-QoL outcomes compared with endocrine therapy alone, but determined better scores compared with chemotherapy. HR-QoL was specifically assessed in premenopausal patients treated with ribociclib, showing similar scores compared with postmenopausal patients. Conclusions: Despite methodological heterogeneity does not allow a proper comparison, HR-QoL was generally maintained with CDK4/6i. However, differences between abemaciclib, palbociclib and ribociclib exist and mainly rely on the distinct safety profiles of the compounds. These differences should be acknowledged and taken into account in the clinical practice.

العلاقة: volume:7; issue:6; firstpage:100629; journal:ESMO OPEN; https://hdl.handle.net/11390/1237246Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85141976357

الإتاحة: https://doi.org/10.1016/j.esmoop.2022.100629Test
https://hdl.handle.net/11390/1237246Test

المؤلفون: Pagliuca, M., Bencivenga, L., Komici, K., De Angelis, C., Caputo, R., Napolitano, F., Cianniello, D., Di Lauro, V., Rengo, G., de Placido, S., André, F., De Laurentiis, M.

المصدر: Annals of Oncology ; volume 33, page S655 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.07.297Test
https://api.elsevier.com/content/article/PII:S0923753422021482?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422021482?httpAccept=text/plainTest

المؤلفون: Ottaviano, M, Curvietto, M, Rescigno, P, Tortora, M, Palmieri, G, Giannarelli, D, Aieta, M, Assalone, P, Attademo, L, Avallone, A, Bloise, F, Bosso, D, Borzillo, V, Buono, G, Calderoni, G, Caputo, F, Cartenì, G, Cavallero, D, Cavo, A, Ciardiello, F, Conca, R, Conteduca, V, De Falco, S, De Felice, M, De Laurentiis, M, De Placido, P, De Placido, S, De Santo, I, De Stefano, A, Della Corte, CM, Di Franco, R, Di Lauro, V, Fabbrocini, A, Federico, P, Festino, L, Giordano, P, Giuliano, M, Gridelli, C, Grimaldi, AM, Lia, M, Marretta, AL, Massa, V, Mennitto, A, Merler, S, Merz, V, Messina, C, Messina, M, Milano, M, Minisini, AM, Montesarchio, V, Morabito, A, Morgillo, F, Mucci, B, Nappi, L, Napolitano, F, Paciolla, I, Pagliuca, M, Parola, S, Pepe, S, Petrillo, A, Piantedosi, F, Piccin, L, Picozzi, F, Pietroluongo, E, Pignata, S, Prati, V, Riccio, V, Rosanova, M, Rossi, A, Russo, A, Salati, M, Santabarbara, G, Sbrana, A, Simeone, E, Silvestri, A, Spada, M, Tarantino, P, Taveggia, P, Tomei, F, Vincenzo, T, Trapani, D, Trojanello, C, Vanella, V, Vari, S, Ventriglia, J, Vitale, MG, Vitiello, F, Vivaldi, C, von Arx, C, Zacchi, F, Zampiva, I, Zivi, A, Daniele, B, Ascierto, PA, SCITO (Società Campana di ImmunoTerapia Oncologica)

المساهمون: Rescigno, Pasquale

مصطلحات موضوعية: SCITO (Società Campana di ImmunoTerapia Oncologica), Humans, Pneumonia, Viral, Coronavirus Infections, Neoplasms, Prevalence, Medical Oncology, Infection Control, Geography, Adult, Italy, Female, Male, Drug Prescriptions, Pandemics, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Time-to-Treatment, Surveys and Questionnaires, Practice Patterns, Physicians', Oncologists, Betacoronavirus, Antineoplastic Agents, Immunological, B7-H1 Antigen, COVID-19, SARS-CoV-2

الوصف: BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. METHODS: This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options. RESULTS: This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. CONCLUSION: Our study highlights the efforts of Italian oncologists to maintain high standards of care ...

وصف الملف: Print; application/pdf

العلاقة: Journal for immunotherapy of cancer, 2020, 8 (2); https://repository.icr.ac.uk/handle/internal/4346Test

الإتاحة: https://doi.org/10.1136/jitc-2020-001154Test
https://repository.icr.ac.uk/handle/internal/4346Test

المؤلفون: Blondeaux, E., Boni, L., Ruelle, T., Di Lauro, V., Molinelli, C., Piezzo, M., Fratini, B., Poggio, F., Pugliese, P., Ferzi, A., Buzzatti, G., Russo, S., Garrone, O., Gasparro, S., D'Alonzo, A., De Laurentiis, M., Fabi, A., Arpino, G., Bighin, C., Del Mastro, L.

المصدر: Annals of Oncology ; volume 32, page S497-S498 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2021.08.590Test
https://api.elsevier.com/content/article/PII:S0923753421028192?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753421028192?httpAccept=text/plainTest

المؤلفون: Palmieri, G., Giuliano, M., Tortora, M., Formisano, P., Malfitano, A.M., D'Esposito, V., Botti, G., Marretta, A.L., Margherita, V., Di Lauro, V., Daniele, B., De Placido, S., Verde, A., Ottaviano, M.

المصدر: Annals of Oncology ; volume 31, page S1080 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2020.08.1447Test
https://api.elsevier.com/content/article/PII:S0923753420414437?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753420414437?httpAccept=text/plainTest

المؤلفون: von Arx, C., Calabrese, A., Martinelli, C., Di Lauro, V., Grimaldi, V., Pensabene, M., Caputo, R., Cerillo, I., Cianniello, D., Buono, G., Verrazzo, A., Pacilio, C., Di Rella, F., Nuzzo, F., De Laurentiis, M.

المصدر: Annals of Oncology ; volume 34, page S370 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2023.09.625Test
https://api.elsevier.com/content/article/PII:S0923753423014618?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753423014618?httpAccept=text/plainTest

المؤلفون: Santorsola M., Di Lauro V., Nasti G., Caraglia M., Capuozzo M., Perri F., Cascella M., Misso G., Ottaiano A.

المساهمون: Santorsola, M., Di Lauro, V., Nasti, G., Caraglia, M., Capuozzo, M., Perri, F., Cascella, M., Misso, G., Ottaiano, A.

مصطلحات موضوعية: breast cancer, colorectal cancer, non-small-cell lung cancer, phase III studie, tumour burden

الوصف: Background: Randomised phase III clinical trials represent a methodological milestone to select effective drugs against metastatic cancers. In this context, and particularly in the efficacy assessment of biologic drugs, the initial metastatic tumour burden is a strong prognostic factor. Methods: A systematic literature review of randomised, phase III, first-line, clinical trials in metastatic breast, colorectal, and lung cancers, published from 2016 to 2021, was performed. Three groups of variables were collected: identity-, method-(including tumour burden assessment) and outcome-related. Results: Seventy trials were selected. A large portion of studies (41.4%) focused on the effects of biologic agents (signal inhibitors and immuno-therapies). A definition of low-burden disease based predominantly on the number of involved organs was reported in 28.6% of studies. No explicit reference to oligo-metastatic disease was found either in inclusion/exclusion criteria or in final descriptive data analyses. Disease extent, heterogeneously defined, was a stratification factor for randomisation in only 25.7% of studies. In two studies, a significant imbalance between arms in patients with low-burden disease was revealed. Conclusions: Attention to initial tumour burden in designing future clinical trials (including the harmonisation of definitions and the reporting of eventual oligo-metastatic disease, complete estimates of tumour volume, and its consideration as a stratification factor) should be increased.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35805034; info:eu-repo/semantics/altIdentifier/wos/WOS:000822179000001; volume:14; issue:13; firstpage:3262; journal:CANCERS; https://hdl.handle.net/11591/483415Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85133189192

الإتاحة: https://doi.org/10.3390/cancers14133262Test
https://hdl.handle.net/11591/483415Test